日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验:在初诊晚期卵巢癌患者中,使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价(FZOCUS-1):一项多中心、随机、双盲、安慰剂对照试验

Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning

Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial

替奈普酶治疗缺血性卒中后 4.5 至 24 小时内的急性非大血管闭塞:OPTION 随机临床试验

Ma, Gaoting; Mo, Ran; Zuo, Yingting; Ma, Qingfeng; Zhao, Guangjian; Yao, Xiaoxi; Liang, Ji; Zhou, Li; He, Yong; Long, Faqing; Yuan, Zhengzhou; Liu, Lei; Han, Guosheng; Tan, Yan; Ai, Zhibing; Cai, Chunsheng; Liu, Juan; Zhang, Liyong; Yang, Haihua; Yi, Tingyu; Li, Li; Fu, Yao; Zhang, Yanxing; Shao, Xiangzhong; Yu, Zhipeng; Wu, Saizhen; Du, Yanqiu; Mao, Lingqun; Guo, Hongling; Chen, Xufeng; Chen, Yifei; Zhao, Qiong; Chi, Liyi; Liu, Yi; Zhang, Haochun; Li, Guangzong; Meng, Shujuan; Wu, Yifan; Wu, Jieying; Jiang, Ziying; Lei, Shaoyuan; Gao, Daiquan; Zhong, Lianmei; Fiehler, Jens; Wang, Duolao; Nguyen, Thanh N; Saver, Jeffrey L; Hao, Junwei

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

乐伐替尼联合经动脉化疗栓塞术和PD-1抑制剂作为不可切除的中晚期肝细胞癌转化疗法:一项II期临床试验和探索性生物分子研究

Zhang, Xiaoyun; Cai, Haozheng; Peng, Wei; Wang, Haiqing; Wu, JiaYi; Zhu, Xinrui; Guo, Weixin; Xie, Fei; Zhang, Yu; Wang, Ming; Yu, Yu; Zhou, Yongjie; Li, Chuan; Shen, Junyi; Liu, Chang; Yang, Yu; Jiang, Xiaozhong; Li, Qiu; Chen, Weixia; Shi, Yujun; Lu, Wusheng; Sun, Xin; Feng, Xielin; Yan, Maolin; Cheng, Shuqun; Wen, Tianfu

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi

Altitude hypoxia and hypoxemia: pathogenesis and management

高原低氧血症:发病机制和治疗

Cai, Chunmei; Ni, Guohua; Chen, Lei; Deng, Cheng; Chai, Shengjun; Wang, Rui; Zhang, Rong; Luo, Fengming; Ge, Ri-Li

PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

PRIME-HFrEF试验:一项针对心力衰竭的随机、双盲、多剂量脐带间充质干细胞治疗方案

Han, Wei; Jiao, Yuheng; Chen, Wei; Gong, Xin; Hu, Hao; Xin, Yuanfeng; Guan, Sibin; Zhao, Jun; Zhang, Qi; Yang, Bing; Pan, Jingwei; Wang, Haiyan; Lu, Qing; Chu, Shuguang; Cai, Dihui; Zheng, Liang; Jia, Wenwen; He, Zhiying; Yang, Huangtian; Sun, Yi Eve; Liu, Zhongmin

Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder

帕金森病伴快速眼动睡眠行为障碍患者的代谢组学和蛋白质组学特征独特

Shao, Yaping; Wang, Jing; Liu, Yaping; Ni, Yang; Liu, Zijiao; Li, Yanli; Jia, Qiqi; Li, Qi; Wang, Xiaolin; Li, Tianbai; Liu, Meichen; Zhang, Shuining; Guo, Yanming; Guo, Xisa; Wang, Dali; Liu, Yang; Liu, Cong; Cai, Huaibin; Ning, Yuping; Zhang, Jihui; Xu, Guowang; Le, Weidong

Glucocorticoids elevate clear cell renal cell carcinoma sensitivity to HIF-2α inhibitors by suppressing H4K12 lactylation

糖皮质激素通过抑制H4K12乳酸化作用,提高透明细胞肾细胞癌对HIF-2α抑制剂的敏感性。

Zhang, Kenan; He, Lin; Wang, Yizhou; Qin, Sen; Yu, Chunyu; Zheng, Enrun; Zhang, Zedan; Xu, Yawei; Chen, Xiaolin; Liu, Yanhua; Liu, Xiaoya; Guan, Sudun; Xia, Lu; Suo, Feiya; Pei, Fei; Du, Juan; Su, Yiran; Li, Yanze; Wu, Yu; Zhou, Xuehong; Zhou, Jingcheng; Cai, Lin; Tang, Xinjing; Zhang, Zheng; Shang, Yongfeng; Zhang, Qing; Gong, Kan; Sun, Luyang

Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma

神经生长因子信号通路的激活限制了肝细胞癌对乐伐替尼的反应

Xu, Minghao; Zheng, Yimin; Zhao, Longtao; Wang, Siwei; Chen, Junbo; Fu, Zhongchi; Ma, Aying; Liang, Bugang; Huang, Yilan; Xu, Haihan; Wang, Yue; Ai, Yingjie; Zeng, Haiying; Gao, Chao; Cai, Jiabin; Ke, Aiwu; Fan, Jia

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者:一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析(SYSUCC-020试验)

Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen